drugset
drugset / Trial / NCT05717764

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

NCT05717764 ↗

Phase 3 Not yet recruiting 500 enrolled CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, positive-controlled, multicenter Phase Ш study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with capecitabine versus capecitabine monotherapy in patients with recurrent metastatic nasopharyngeal carcinoma.

Timeline

Start
2023-02
Primary completion
2026-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule — Intravenous
Background Capecitabine Small molecule — Oral

Indications

nasopharyngeal carcinoma